Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer

Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheon, Yun-Hong, Kim, Moon Jin, Kang, Min Gyu, Kim, Hee Jin, Lee, Sang Su, Kim, Cha Young, Jeon, Dae-Hong, Kim, Yu Eun, Lee, Gyeong-Won
Formato: Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104451/
https://www.ncbi.nlm.nih.gov/pubmed/21623617
http://dx.doi.org/10.3349/ymj.2011.52.4.695
Descripción
Sumario:Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum-based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

Ejemplares similares